Cleared Traditional

PENTACAM SCHEIMPFLUG CAMERA (K030719) - FDA 510(k) Clearance

Class II Ophthalmic device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K030719 · Oculus Optikgerate GmbH · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2003
Decision
193d
Days
Class 2
Risk

K030719 is an FDA 510(k) clearance for the PENTACAM SCHEIMPFLUG CAMERA. Classified as Device, Analysis, Anterior Segment (product code MXK), Class II - Special Controls.

Submitted by Oculus Optikgerate GmbH (Woodinville, US). The FDA issued a Cleared decision on September 16, 2003 after a review of 193 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.1850 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Oculus Optikgerate GmbH devices

Submission Details

510(k) Number K030719 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 07, 2003
Decision Date September 16, 2003
Days to Decision 193 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
83d slower than avg
Panel avg: 110d · This submission: 193d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MXK Device, Analysis, Anterior Segment
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.1850
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - MXK Device, Analysis, Anterior Segment

All 22
Devices cleared under the same product code (MXK) and FDA review panel - the closest regulatory comparables to K030719.
Pentacam® Cornea OCT
K251848 · Oculus Optikger?te GmbH · Mar 2026
Tomey Optical Biometer OA-2000 (OA-2000)
K252348 · Tomey Corporation · Dec 2025
BOSS™
K223700 · Intelon Optics, Inc. · Aug 2024
MYAH
K222933 · Visia Imaging S.R.L. · Jun 2023
MYAH
K211868 · Visia Imaging S.R.L. · Mar 2022
Myopia Master
K202989 · Oculus Optikger?te GmbH · Jul 2021